241 related articles for article (PubMed ID: 27315759)
1. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
Pechère-Bertschi A; Herpin D; Lefebvre H
Ann Endocrinol (Paris); 2016 Jul; 77(3):226-34. PubMed ID: 27315759
[TBL] [Abstract][Full Text] [Related]
2. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 6: Adrenal surgery.
Steichen O; Amar L; Chaffanjon P; Kraimps JL; Ménégaux F; Zinzindohoue F
Ann Endocrinol (Paris); 2016 Jul; 77(3):220-5. PubMed ID: 27297451
[TBL] [Abstract][Full Text] [Related]
3. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook.
Amar L; Baguet JP; Bardet S; Chaffanjon P; Chamontin B; Douillard C; Durieux P; Girerd X; Gosse P; Hernigou A; Herpin D; Houillier P; Jeunemaitre X; Joffre F; Kraimps JL; Lefebvre H; Ménégaux F; Mounier-Véhier C; Nussberger J; Pagny JY; Pechère A; Plouin PF; Reznik Y; Steichen O; Tabarin A; Zennaro MC; Zinzindohoue F; Chabre O
Ann Endocrinol (Paris); 2016 Jul; 77(3):179-86. PubMed ID: 27315757
[TBL] [Abstract][Full Text] [Related]
4. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA?
Baguet JP; Steichen O; Mounier-Véhier C; Gosse P
Ann Endocrinol (Paris); 2016 Jul; 77(3):187-91. PubMed ID: 27087531
[TBL] [Abstract][Full Text] [Related]
5. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
6. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
Riester A; Reincke M
Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
[TBL] [Abstract][Full Text] [Related]
7. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
Matsuda Y; Kawate H; Matsuzaki C; Sakamoto R; Shibue K; Ohnaka K; Anzai K; Nomura M; Takayanagi R
Endocr J; 2016; 63(3):249-55. PubMed ID: 26727302
[TBL] [Abstract][Full Text] [Related]
8. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: Subtype diagnosis.
Bardet S; Chamontin B; Douillard C; Pagny JY; Hernigou A; Joffre F; Plouin PF; Steichen O
Ann Endocrinol (Paris); 2016 Jul; 77(3):208-13. PubMed ID: 27036860
[TBL] [Abstract][Full Text] [Related]
9. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
Yoneda T; Demura M; Takata H; Kometani M; Karashima S; Yamagishi M; Takeda Y
J Clin Endocrinol Metab; 2012 Apr; 97(4):1109-13. PubMed ID: 22337911
[TBL] [Abstract][Full Text] [Related]
10. Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism.
Nakamaru R; Yamamoto K; Akasaka H; Rakugi H; Kurihara I; Yoneda T; Ichijo T; Katabami T; Tsuiki M; Wada N; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Kawashima J; Inagaki N; Fujita M; Oki K; Kamemura K; Tanabe A; Naruse M;
Hypertension; 2021 Feb; 77(2):537-545. PubMed ID: 33356395
[TBL] [Abstract][Full Text] [Related]
11. Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
Nakano Y; Yoshimoto T; Fukuda T; Murakami M; Bouchi R; Minami I; Hashimoto K; Fujii Y; Kihara K; Ogawa Y
Intern Med; 2018 Sep; 57(17):2459-2466. PubMed ID: 29709927
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of drug-based and surgical treatments for primary aldosteronism.
Steichen O; Lorthioir A; Zinzindohoue F; Plouin PF; Amar L
Adv Chronic Kidney Dis; 2015 May; 22(3):196-203. PubMed ID: 25908468
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
14. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism.
Zennaro MC; Jeunemaitre X
Ann Endocrinol (Paris); 2016 Jul; 77(3):214-9. PubMed ID: 27315758
[TBL] [Abstract][Full Text] [Related]
15. ARAs to the RESCUE.
Kaplan NM
J Am Soc Hypertens; 2016 Mar; 10(3):187-8. PubMed ID: 27408946
[No Abstract] [Full Text] [Related]
16. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically.
Ahmed AH; Gordon RD; Sukor N; Pimenta E; Stowasser M
J Clin Endocrinol Metab; 2011 Sep; 96(9):2904-11. PubMed ID: 21778218
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era.
Catena C; Colussi G; Sechi LA
Eur J Endocrinol; 2013 Jan; 168(1):C1-5. PubMed ID: 23082005
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological treatment of aldosterone excess.
Deinum J; Riksen NP; Lenders JW
Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
[TBL] [Abstract][Full Text] [Related]
19. Outcomes analysis of surgical and medical treatments for patients with primary aldosteronism.
Park KS; Kim JH; Yang YS; Hong AR; Lee DH; Moon MK; Choi SH; Shin CS; Kim SW; Kim SY
Endocr J; 2017 Jun; 64(6):623-632. PubMed ID: 28458337
[TBL] [Abstract][Full Text] [Related]
20. Eplerenone use in primary aldosteronism during pregnancy.
Cabassi A; Rocco R; Berretta R; Regolisti G; Bacchi-Modena A
Hypertension; 2012 Feb; 59(2):e18-9. PubMed ID: 22146514
[No Abstract] [Full Text] [Related]
[Next] [New Search]
